Drug Patent Watch
OCTOBER 4, 2021
This is my talk from the 14th Annual Portfolio Planning and Partnership for Generic Conference. I discuss: Identifying generic entry opportunities at the earliest stages Discovering opportunities that avoid litigation…. The post Generic Portfolio Management, Partnering with Brands, and Staying Competitive appeared first on DrugPatentWatch - Make Better Decisions.
Drug Discovery Today
OCTOBER 28, 2021
Highly consistent and scalable supply of lab grown human skeletal muscle cells provide an effective and biologically relevant tool for research and drug development in conditions as diverse as metabolic and muscle diseases and ageing.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Channels
OCTOBER 8, 2021
Today’s guest post comes from Bill Dupere, Practice Lead and VP of Market Access Solutions and Eric Willis, VP of Operations Hub and Reimbursement Services at TrialCard. Bill and Eric discuss the complexities of digital patient support program technologies and introduce TrialCard’s integrated suite of solutions. To learn more, please contact Trialcard at sales@trialcard.com or visit them in booth #416 at the upcoming Asembia Specialty Pharmacy Summit from October 26 to 29, 2021.
The Pharma Data
OCTOBER 29, 2021
– Presbyopia, or age-related blurry near vision, is a common, progressive condition that reduces the eye’s ability to focus on near objects, affecting most adults over the age 40 – Phase 3 clinical studies demonstrated VUITY works in as early as 15 minutes and lasts for up to 6 hours, as measured on day 30, to improve near and intermediate vision without impacting distance vision – Allergan, an AbbVie company, continues legacy of eye care innovation with VUITY, a first-of
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Crown Bioscience
OCTOBER 27, 2021
In this post we explore how using a range of translational preclinical models can be used to accelerate the discovery and validation of predictive biomarkers, with the goal of de-risking drug development to increase the likelihood of clinical success for therapeutic candidates.
Olympian Clinical Research
OCTOBER 14, 2021
If you’re thinking about joining a clinical trial, there are many benefits you could look forward to. It’s not just the potential for medical breakthroughs that has people excited – it’s also the feeling of being part of something important and potentially life-changing. But how can you tell if clinical trials are right for you? We’ve outlined five reasons why joining a clinical trial might be in your best interest.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Drug Discovery Today
OCTOBER 13, 2021
Construction of No.1 Birmingham Health Innovation Campus (BHIC) in Selly Oak is underway, marking a major milestone for the region’s rapidly growing life sciences sector.
Drug Channels
OCTOBER 25, 2021
By reader request, we present below a channel flow chart illustrating the buy-and-bill process for provider-administered drugs. This chart complements Follow the Dollar: The U.S. Pharmacy Distribution and Reimbursement System for Patient-Administered, Outpatient Brand-name Drugs. To further help you understand this channel, I have also included a brief video to explain the buy-and-bill system.
The Pharma Data
OCTOBER 29, 2021
Scemblix provides much-needed and long-awaited new option for patients with chronic myeloid leukemia (CML) who suffer with intolerance or inadequate response after at least two previous tyrosine kinase inhibitor (TKI) treatments 1 In the pivotal Phase III ASCEMBL trial, Scemblix demonstrated significant and clinically meaningful superiority in major molecular response (MMR) rate vs.
The ChEMBL-og
OCTOBER 13, 2021
If you use ChEMBL via the interface and are interested in programmatic approaches then join our webinar on November 10th @ 15:30 to find out more ! In this webinar, we'll provide an overview of the ChEMBL and UniChem APIs and work through some common examples. In the meantime, don’t forget that we have further documentation on our web services as well as a recent ChEMBL webinar, a Blog and series of FAQs.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Crown Bioscience
OCTOBER 12, 2021
In this post, we discuss modern flow cytometry as a game-changer for cell functional assays, immune monitoring, and function-based screening of drug candidates to support and accelerate your biomarker strategy and translational programs.
Drug Patent Watch
OCTOBER 19, 2021
Annual Drug Patent Expirations for CALCIUM+GLUCONATE+IN+SODIUM+CHLORIDE Calcium Gluconate In Sodium Chloride is a drug marketed by Fresenius Kabi Usa and Hq Spclt Pharma and is included in two NDAs. It…. The post New patent for Hq Spclt drug CALCIUM GLUCONATE IN SODIUM CHLORIDE appeared first on DrugPatentWatch - Make Better Decisions.
The Anticancer Fund
OCTOBER 22, 2021
22 October 2021 Language EN Drug repurposing is a strategy for identifying new uses for approved drugs, outside the scope of the original indication. It is one of the focus areas of the Anticancer Fund. Below, we have listed recent findings about the repurposing of generic drugs in oncology. Our intention is to help bring these findings to the attention of the broader cancer research community.
Drug Channels
OCTOBER 12, 2021
Payers have long sought to disrupt the buy-and-bill channel. Coming out of the pandemic (maybe?), specialty pharmacies—via white, brown, and clear bagging—continue to displace buy-and-bill distribution channels for provider-administered oncology drugs. Check out the latest 2021 data below. The battle for the specialty patient pits hospitals against insurers—and their respective specialty pharmacies.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
The Pharma Data
OCTOBER 29, 2021
Merck known as MSD outside the United States and Canada, moment blazoned that it has withdrawn its Premerger Announcement and Report Form under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “ HSR Act”), in connection with Merck’s pending accession of Acceleron PharmaInc. (Nasdaq XLRN). As preliminarily blazoned on October 12, 2021, Merck commenced, through a attachment, Astros Merger Sub,Inc., a cash tender offer to buy all outstanding shares of common stock of Accele
The ChEMBL-og
OCTOBER 4, 2021
Over the years we've added many new features to ChEMBL and some of these have proved to be particularly valuable to our users. However, our resources are finite, and in order to continue to bring you exciting new improvements, we may sometimes need to re-evalutate features that are not well used and/or costly to maintain. To get the clearest possible view of which of our current data types, formats and access mechanisms are most important to you, we've put together a brief survey.
Crown Bioscience
OCTOBER 5, 2021
Review key questions on preclinical models and rare cell analysis technology for assessing CAR-T cell therapies from our recent webinar , answered by Dr. Rajendra Kumari, Global Head of Scientific Communication.
Drug Patent Watch
OCTOBER 20, 2021
DrugPatentWatch has been ranked the “Best Biopharmaceuticals Commercial Business Intelligence Platform” by Global Health & Pharma News This award is dedicated to honoring the innovation, determination and outstanding levels of…. The post DrugPatentWatch Ranked Best Biopharmaceuticals Commercial Business Intelligence Platform appeared first on DrugPatentWatch - Make Better Decisions.
Drug Discovery Today
OCTOBER 28, 2021
Cambridge, UK, 28 October 2021: Sphere Fluidics, a company that has developed and is commercialising single cell analysis systems underpinned by its proprietary picodroplet technology, announced today that it has closed a $40 million (circa £30 million) investment round. The round was led by Sofinnova Partners (Paris, France) and Redmile Group (San Francisco, USA) co-investing on equal terms.
Drug Channels
OCTOBER 19, 2021
Hospitals and health systems are rapidly expanding their internal specialty pharmacies—and they’re using questionable tactics to boost revenues and profits. A new American Society of Hospital Pharmacists (ASHP) survey of health system pharmacies offers fresh insights into how these systems steer prescriptions to their internal specialty pharmacies: For most health systems' in-house specialty pharmacies, more than 90% of specialty prescriptions are written by system-employed physicians.
The Pharma Data
OCTOBER 29, 2021
PfizerInc. and BioNTech moment blazoned that theU.S. Food and Drug Administration (FDA) has authorized for exigency use the Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 times of age ( also appertained to as 5 to< 12 times). For this age group, the vaccine is to be administered in a two- cure authority of 10-µg boluses given 21 days piecemeal.
The Strateos Blog: Drug Discovery
OCTOBER 8, 2021
Strateos was pleased to sponsor a webinar on Sept 27, 2021 to discuss how a single unified cloud-based software platform can overcome current operational inefficiencies in life science R&D labs. Alok Gupta, SVP of Engineering, Venkat (VK) Eswarakrishanan, Product Manager, and Vanessa Biggers, Director of Engineering, Scientific Technologies at Strateos led the discussion.
Crown Bioscience
OCTOBER 2, 2021
Dr Davy Ouyang, CrownBio Vice President of Scientific Research & Innovation answers the most popular questions from his recent syngeneic model webinar , covering the latest research, model developments , and platforms for moving past syngeneics for advanced immuno-oncology studies.
Drug Patent Watch
OCTOBER 20, 2021
DrugPatentWatch’s Custom Market Surveillance provides you with a robust platform to monitor your business opportunities from every angle. You’re monitoring your business, but you’re too busy to sift through data.…. The post DrugPatentWatch Custom Market Surveillance appeared first on DrugPatentWatch - Make Better Decisions.
Practical Cheminformatics
OCTOBER 24, 2021
One of the most common tasks in Cheminformatics is exploratory data analysis (EDA). Given a new dataset, we often need to rapidly explore the chemistry in a set containing hundreds, or even thousands, of molecules. One useful technique for EDA is the Bemis-Murcko framework. This technique, originally published by Guy Bemis and Mark Murcko, provides a simple but elegant means of grouping molecules.
Drug Channels
OCTOBER 1, 2021
Today’s guest post comes from David Fidler, Senior Director of Product Innovation at ConnectiveRx. David discusses how electronic prior authorization (ePA) and first-fill, buy-down programs can boost patient adherence to specialty therapies. On November 3rd at 1:00 pm ET, ConnectiveRx will host First Fill, No Wait: How to Make it Happen , a free webinar about copay ePA.
The Pharma Data
OCTOBER 28, 2021
Lower talk, further action New report patronized by ViiV Healthcare provides roadmap to achieve health equity by 2040. ViiV Healthcare blazoned the release of Achieving health equity a roadmap to barring difference, a new report conducted by Economist Impact, a division of The Economist Group, that explores the openings that could be created by barring health difference in the UK and US over the coming 20 times, while charting a bold course for unified action.
The Connected Lab
OCTOBER 6, 2021
Exploring how digital transformation will revolutionize process optimization and decision-making within the pharmaceutical industry Digital transformation is ushering in a new era for pharmaceutical research and manufacturing, characterized by advanced solutions, such as automation, networked technologies and machine learning, that support faster decision-making and more efficient process control.
Nvidia Developer: Drug Discovery
OCTOBER 5, 2021
A new study out of the Massachusetts Institute of Technology (MIT) could arm healthcare workers with the information needed to effectively treat COVID-19. A new study out of the Massachusetts Institute of Technology (MIT) could arm healthcare workers with the information needed to effectively treat COVID-19 patients. Recently published in the Proceedings of the National Academy of Sciences , the research develops a deep learning model that determines the best drug combinations for fighting the v
Drug Patent Watch
OCTOBER 20, 2021
Before the passage of the Biologic Patent Transparency Act DrugPatentWatch’s biologic patent data was cited as a reason why the law should not be passed. Thankfully, the Act advanced, and…. The post Updating the DrugPatentWatch Biologics Module appeared first on DrugPatentWatch - Make Better Decisions.
PerkinElmer
OCTOBER 26, 2021
Since the World Health Organization (WHO) declared the novel coronavirus (COVID-19) outbreak a global pandemic on March 11, 2020, researchers around the world have been working tirelessly to discover effective preventive treatments and therapeutic agents. Currently, the FDA has only approved one drug, Veklury (remdesivir), for treatment of COVID-19.
Drug Channels
OCTOBER 22, 2021
Today’s guest post comes from Scott Johnsen, VP of Product at Kalderos. Scott discusses the advantages of using artificial intelligence and machine learning to efficiently process reimbursement data and avoid duplicates. Learn more about Kalderos’ solutions to solve drug discount management challenges at scale during a free webinar on November 17: The Power of the Platform: How a Trusted Network Delivers Outcomes That Are a Win for All.
The Pharma Data
OCTOBER 28, 2021
PFIZER AND BIONTECH TO GiveU.S. GOVERNMENT AN Fresh 50 MILLION PEDIATRIC Boluses OF COVID-19 VACCINE TO SUPPORT Farther PREPAREDNESS FOR FUTURE NEEDS. PfizerInc. (NYSE PFE) and BioNTech SE (Nasdaq BNTX) moment blazoned that theU.S. government has bought 50 million further boluses of the companies’COVID-19 vaccine. TheU.S. will admit these fresh boluses to continue to support preparedness for pediatric vaccinations, including securing vaccines for children under 5 times of age, should they admit
Eye on FDA
OCTOBER 28, 2021
Recently it was reported that the President Biden appears ready to nominate former FDA Commissioner Robert Califf to boomerang back and head the agency for a second time. If so, he returns to very different circumstances than when he left FDA in January 2017 after an 11-month stay. While FDA is accustomed to controversy while making difficult decisions, lately, it is much more than that.
Expert insights. Personalized for you.
144 
Let's personalize your content